Enliven therapeutics to present at td cowen's 44th annual health care conference

Boulder, colo., feb. 27, 2024 (globe newswire) -- enliven therapeutics, inc. (enliven) (nasdaq: elvn), a clinical-stage precision oncology focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will participate in a panel discussion at td cowen's 44th annual health care conference in boston, ma, on tuesday, march 5, 2024, at 12:50 p.m. et.
ELVN Ratings Summary
ELVN Quant Ranking